UBX 363
Alternative Names: UBX-363Latest Information Update: 15 Feb 2024
At a glance
- Originator Ubix Therapeutics
- Class Antineoplastics
- Mechanism of Action Lymphocyte specific protein tyrosine kinase p56(lck) degraders
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Precursor T-cell lymphoblastic leukaemia-lymphoma
Most Recent Events
- 09 Dec 2023 Preclinical trials in Precursor T-cell lymphoblastic leukaemia-lymphoma in South Korea (PO)
- 09 Dec 2023 Pharmacodynamics data from preclinical study in Precursor T-cell lymphoblastic leukaemia lymphoma presented at the 65th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2023)